# Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse

> **NCT07686965** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 191 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Maintenance Treatment
- Hematopoetic Stem Cell Transplantation

## Interventions

- **DRUG:** Lisaftoclax Plus Azacitidine

## Key facts

- **NCT ID:** NCT07686965
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2030-08-10
- **Final completion:** 2030-08-10
- **Target enrollment:** 191 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686965, "Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*